The label expansion couls help J&J establish Tremfya as a successor to Stelara, which is now facing a growing biosimilar ...

DelveInsight's "DARZALEX Market Size, Forecast, and Market Insight Report" highlights the details around DARZALEX, a human ...

DARZALEX has significant market potential as a leading monoclonal antibody for multiple myeloma treatment. Its approval in various combinations for both newly diagnosed and relapsed/refractory ...

A vaccine's ability to generate long-lasting, high-affinity antibodies hinges on a delicate balance. Upon exposure to a vaccine or pathogen, B cells scramble to refine their defenses, rapidly mutating ...

Type I allergy, an IgE antibody triggered hypersensitivity disease, represents a common public health problem affecting about one third of the world´s population. Upon exposure to allergens, IgE ...

The FDA granted orphan drug designation to HLX22 for gastric cancer, advancing global phase 3 trials to improve first-line ...

Shanghai Henlius Biotech, Inc. (2696.HK) announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for HLX22, the company's innovative anti-HER2 monoclonal ...

Operator Good afternoon, ladies and gentlemen, and welcome to the INOVIO Pharmaceuticals fourth quarter 2024 financial results conference call. At this time, all lines are in listen-only mode.

Multiple myeloma is a type of cancer characterized by the uncontrolled proliferation of clonal plasma cells, which leads to ...

FDA grants Fast Track designation to Johnson & Johnson’s investigational therapy nipocalimab for the treatment of moderate-to-severe Sjögren’s disease, which could be the first targeted therapy ever ...

Celex Oncology’s first attendance at Bio-Europe Spring 2025 follows their recent win at the 2024 EIT Health Catapult ...